{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Wockhardt Ltd
Why is Wockhardt falling/rising?
On 03-Dec, Wockhardt Ltd’s stock price declined sharply by 5.33%, closing at ₹1,415.15, reflecting a notable reversal after two days of gains despite strong recent operating profit growth and rising investor participation.
Wockhardt Sees Robust Trading Activity Amidst Sector Outperformance
Wockhardt Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has emerged as one of the most actively traded stocks by value on 2 December 2025. The stock demonstrated notable trading volumes and value turnover, outperforming its sector peers and reflecting heightened investor interest and liquidity in the market.
Is Wockhardt technically bullish or bearish?
As of December 1, 2025, Wockhardt's technical trend is mildly bearish, influenced by bearish weekly MACD and KST indicators, despite some bullish signals from Bollinger Bands and strong long-term returns compared to the Sensex.
Wockhardt Stock Analysis: Technical Momentum and Market Assessment
Wockhardt’s recent trading activity reveals a notable shift in technical momentum, with key indicators signalling a transition from a bearish stance to a more nuanced mildly bearish outlook. The stock’s price movement, combined with mixed signals from MACD, RSI, and moving averages, offers investors a complex picture amid a volatile market backdrop.
How has been the historical performance of Wockhardt?
Wockhardt's net sales increased to 3,012.00 Cr in March 2025, up from 2,651.00 Cr in March 2023, but profitability remains a concern with a profit before tax of -16.00 Cr and a profit after tax loss of -57.00 Cr. Total liabilities rose to 7,586.00 Cr, and cash flow from operating activities was negative at -22.00 Cr, indicating ongoing financial challenges despite sales recovery.
Wockhardt Sees High-Value Trading Amidst Volatile Market Activity
Wockhardt Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has emerged as one of the most actively traded stocks by value on 1 December 2025. The stock demonstrated significant price movement and trading volume, reflecting heightened investor interest and notable liquidity in a volatile market environment.
Wockhardt Hits Day High with Strong Intraday Surge
Wockhardt recorded a notable intraday rally on 1 December 2025, reaching its highest price point of the day amid a broader positive market environment. The pharmaceutical company’s shares outpaced sector and benchmark indices, reflecting a significant shift in trading momentum after a brief period of decline.
Wockhardt’s Market Assessment Reflects Mixed Signals Amidst Financial and Technical Shifts
Wockhardt’s recent market evaluation reveals a complex interplay of financial performance and technical indicators, prompting a revision in the company’s assessment. While the pharmaceutical firm posted strong quarterly results, several long-term fundamentals and technical trends suggest a cautious outlook for investors.
Wockhardt Technical Momentum Shifts Amid Mixed Market Signals
Wockhardt's stock price momentum has experienced a notable shift as recent technical indicators reveal a predominantly bearish outlook across multiple timeframes. Despite some bullish signals on longer-term charts, the overall technical landscape suggests caution for investors navigating the Pharmaceuticals & Biotechnology sector.
Why is Wockhardt falling/rising?
As of 07-Nov, Wockhardt Ltd's stock price is Rs 1,336.85, down 1.09% and underperforming its sector. Despite a recent positive operating profit growth, concerns about pledged promoter shares and weak long-term fundamentals suggest potential valuation challenges.
Is Wockhardt technically bullish or bearish?
As of November 4, 2025, Wockhardt's trend is mildly bearish due to bearish momentum from the MACD and KST indicators, despite some bullish signals from the monthly Bollinger Bands and accumulation indicated by the OBV.
Wockhardt's Stock Shows Mixed Technical Trends Amid Market Evaluation Revision
Wockhardt, a small-cap pharmaceutical company, has recently revised its market evaluation. The stock is currently priced at 1,365.00, reflecting mixed technical indicators. Despite recent weekly gains, the company has faced challenges in longer-term performance, highlighting its fluctuating position within the industry.
Is Wockhardt technically bullish or bearish?
As of November 4, 2025, Wockhardt's trend is mildly bearish, indicated by bearish weekly MACD and KST signals, while the OBV shows underlying bullish strength, resulting in mixed overall sentiment.
Is Wockhardt overvalued or undervalued?
As of November 4, 2025, Wockhardt is considered very expensive and overvalued with a PE ratio of 299.73 and significant premium valuation metrics compared to peers like Sun Pharma and Cipla, despite a strong long-term return of 470.77% and recent underperformance of -3.83% year-to-date.
How has been the historical performance of Wockhardt?
Wockhardt's historical performance shows fluctuating net sales, increasing from 2,651 Cr in Mar'23 to 3,012 Cr in Mar'25, but it continues to struggle with profitability, reporting a loss of -57 Cr in Mar'25 despite improved operating profit. The company faces liquidity challenges with negative cash flow of -22 Cr in Mar'25.
Wockhardt's Strong Financial Metrics Indicate Resilience and Competitive Positioning in Pharma Sector
Wockhardt, a small-cap pharmaceutical company, has demonstrated strong financial performance for the quarter ending September 2025, with notable metrics including a high operating profit to interest ratio and record PBDIT. The company has shown resilience in the market, significantly outperforming the Sensex over the past three years.
How has been the historical performance of Wockhardt?
Wockhardt's historical performance shows fluctuating financial metrics, with net sales increasing to INR 3,012.00 crore by March 2025, but the company reported a net loss of INR -47.00 crore and negative cash flow of INR -22.00 crore, indicating ongoing profitability challenges despite some revenue improvements.
Why is Wockhardt falling/rising?
As of 03-Nov, Wockhardt Ltd's stock price is rising to 1,414.95, up 10.43%, reversing a two-day decline. Despite concerns over increased pledged shares and weak long-term fundamentals, recent positive operating results and a discount compared to peers may be driving the upward movement.
Wockhardt Q2 FY26: Losses Widen Despite Revenue Stability as Operational Challenges Persist
Wockhardt Ltd., the Mumbai-based pharmaceutical and biotechnology company, reported consolidated net losses of ₹90.00 crores for Q2 FY26 (Jun'25), a significant deterioration from the ₹25.00 crores loss reported in the previous quarter and marking a 542.86% widening compared to the ₹14.00 crores loss in the year-ago period. The results come against a backdrop of persistent operational challenges, with the company's stock surging 10.43% post-announcement to close at ₹1,414.95, reflecting market optimism despite the weak quarterly performance.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
